SCHEMBL30299501

SCHEMBL30299501

Nc1cncc(-c2cn3ncnc3c(Nc3ccc(N4CCN(C5COC5)CC4)cc3)n2)n1

nearest known ligand 0.73

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 20/20 0.73
▸ CD63 P08962 6/20 0.73
▸ JAK2 O60674 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25292590 1.00 SYK (0.73) SYKCD63JAK2
SCHEMBL25797068 0.90 SYK (0.59) SYKCD63JAK2
SCHEMBL30299467 0.85 SYK (0.63) SYKCD63JAK2
SCHEMBL25249235 0.85 SYK (0.63) SYKCD63JAK2
Lanraplenib SCHEMBL16820581 0.85 SYK (1.00) SYKCD63JAK2
Lanraplenib SCHEMBL29422916 0.85 SYK (1.00) SYKCD63JAK2
SCHEMBL25799571 0.81 SYK (0.51) SYKCD63JAK2
SCHEMBL25797064 0.81 SYK (0.50) SYKCD63JAK2
SCHEMBL31010502 0.80 SYK (0.49) SYKCD63JAK2
Lanraplenib SCHEMBL16820593 0.80 SYK (0.89) SYKCD63JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4157848-A1 COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS Nanjing Ruijie Pharma Co., Ltd. (CN) 2023-04-05 — — EP claimed
CN-115916782-A Compounds and their use as spleen tyrosine kinase inhibitors 南京瑞捷医药科技有限公司 2023-04-04 — — CN claimed
CN-115916782-B Compounds and their use as inhibitors of spleen tyrosine kinase 南京瑞捷医药科技有限公司 2024-08-13 — — CN disclosed
EP-4157848-A1 COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS Nanjing Ruijie Pharma Co., Ltd. (CN) 2023-04-05 — — EP disclosed
CN-115916782-A Compounds and their use as spleen tyrosine kinase inhibitors 南京瑞捷医药科技有限公司 2023-04-04 — — CN disclosed
Send feedback